Literature DB >> 11427554

Antifungal susceptibility testing of fluconazole by flow cytometry correlates with clinical outcome.

C Wenisch1, C B Moore, R Krause, E Presterl, P Pichna, D W Denning.   

Abstract

Susceptibility testing of fungi by flow cytometry (also called fluorescence-activated cell sorting [FACS]) using vital staining with FUN-1 showed a good correlation with the standard M27-A procedure for assessing MICs. In this study we determined MICs for blood culture isolates from patients with candidemia by NCCLS M27-A and FACS methods and correlated the clinical outcome of these patients with in vitro antifungal resistance test results. A total of 24 patients with candidemia for whom one or more blood cultures were positive for a Candida sp. were included. Susceptibility testing was performed by NCCLS M27-A and FACS methods. The correlation of MICs (NCCLS M27-A and FACS) and clinical outcome was calculated. In 83% of the cases, the MICs of fluconazole determined by FACS were within 1 dilution of the MICs determined by the NCCLS M27-A method. For proposed susceptibility breakpoints, there was 100% agreement between the M27-A and FACS methods. In the FACS assay, a fluconazole MIC of <1 microg/ml was associated with cure (P < 0.001) whereas an MIC of > or =1 microg/ml was associated with death (P < 0.001). The M27-A-derived fluconazole MICs did not correlate with outcome (P = 1 and P = 0.133).

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11427554      PMCID: PMC88170          DOI: 10.1128/JCM.39.7.2458-2462.2001

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  25 in total

1.  Flow cytometry antifungal susceptibility testing of pathogenic yeasts other than Candida albicans and comparison with the NCCLS broth microdilution test.

Authors:  R Ramani; V Chaturvedi
Journal:  Antimicrob Agents Chemother       Date:  2000-10       Impact factor: 5.191

2.  Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole.

Authors:  J R Wingard; W G Merz; M G Rinaldi; T R Johnson; J E Karp; R Saral
Journal:  N Engl J Med       Date:  1991-10-31       Impact factor: 91.245

3.  Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America.

Authors:  J H Rex; T J Walsh; J D Sobel; S G Filler; P G Pappas; W E Dismukes; J E Edwards
Journal:  Clin Infect Dis       Date:  2000-04-20       Impact factor: 9.079

4.  Comparison of relative susceptibilities of Candida species to three antifungal agents as determined by unstandardized methods.

Authors:  J N Galgiani; J Reiser; C Brass; A Espinel-Ingroff; M A Gordon; T M Kerkering
Journal:  Antimicrob Agents Chemother       Date:  1987-09       Impact factor: 5.191

Review 5.  The emergence of fungi as major hospital pathogens.

Authors:  G P Bodey
Journal:  J Hosp Infect       Date:  1988-02       Impact factor: 3.926

6.  Characterization and quantitation of the pharmacodynamics of fluconazole in a neutropenic murine disseminated candidiasis infection model.

Authors:  D Andes; M van Ogtrop
Journal:  Antimicrob Agents Chemother       Date:  1999-09       Impact factor: 5.191

7.  Results of a survey of antifungal susceptibility tests in the United States and interlaboratory comparison of broth dilution testing of flucytosine and amphotericin B.

Authors:  D L Calhoun; G D Roberts; J N Galgiani; J E Bennett; D S Feingold; J Jorgensen; G S Kobayashi; S Shadomy
Journal:  J Clin Microbiol       Date:  1986-02       Impact factor: 5.948

8.  Treatment of Candida albicans fungaemia with fluconazole.

Authors:  W Graninger; E Presteril; B Schneeweiss; B Teleky; A Georgopoulos
Journal:  J Infect       Date:  1993-03       Impact factor: 6.072

9.  Amphotericin B-resistant yeast infection in severely immunocompromised patients.

Authors:  W G Powderly; G S Kobayashi; G P Herzig; G Medoff
Journal:  Am J Med       Date:  1988-05       Impact factor: 4.965

10.  Candida lusitaniae: frequency of recovery, colonization, infection, and amphotericin B resistance.

Authors:  W G Merz
Journal:  J Clin Microbiol       Date:  1984-12       Impact factor: 5.948

View more
  4 in total

Review 1.  Antifungal Susceptibility Testing: Current Approaches.

Authors:  Elizabeth L Berkow; Shawn R Lockhart; Luis Ostrosky-Zeichner
Journal:  Clin Microbiol Rev       Date:  2020-04-29       Impact factor: 26.132

2.  Conidial viability assay for rapid susceptibility testing of Aspergillus species.

Authors:  S Arunmozhi Balajee; Kieren A Marr
Journal:  J Clin Microbiol       Date:  2002-08       Impact factor: 5.948

3.  Rapid susceptibility testing and microcolony analysis of Candida spp. cultured and imaged on porous aluminum oxide.

Authors:  Colin J Ingham; Sjoukje Boonstra; Suzanne Levels; Marit de Lange; Jacques F Meis; Peter M Schneeberger
Journal:  PLoS One       Date:  2012-03-16       Impact factor: 3.240

4.  Susceptibility tests of oropharyngeal Candida albicans from egyptian patients to fluconazole determined by three methods.

Authors:  Noha El-Mashad; Mona F Foad; Niveen Saudy; Dalia A Salem
Journal:  Braz J Microbiol       Date:  2012-06-01       Impact factor: 2.476

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.